E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria

Ashish Kumar Rai, Shital Poojary, Lily Dubey, Pawan Gupta.

Abstract
Background: Second generation antihistamines are first line therapy for chronic spontaneous urticaria (CSU). Sedation has been always a concern as a side effect of antihistamine for both patients and treating dermatologist. It is always better to prefer non-sedative antihistamine for CSU. Bepotastine is such promising non-sedative agent.

Aim and Objectives: The objective of the study was to compare the efficacy and safety of bepotastine and levocetirizine in patients of CSU.

Materials and Methods: This is a double arm, open label, randomized, and controlled study. Out of 99 patients, 50 patients belonged to Group A while 49 belonged to Group B. Subjects in Group A received bepotastine 10 mg twice daily while subjects in Group B received levocetirizine 5 mg once daily for 8 weeks. Patients were evaluated at baseline, day 14, day 28, and day 56 using Urticaria Activity Score (UAS) and Urticaria Control Test (UCT) for efficacy; and visual analog scale (VAS) for safety, that is, sedation.

Results: The fall in mean UAS scores was statistically significant at day 14, day 28, and day 56 for both Groups A and B (P < 0.05) on intragroup comparison. While comparing the overall improvement between the two groups, there was no significant difference in UAS and UCT score at day 14, day 28, and day 56 between Group A and Group B, respectively (P > 0.05). At day 56, there was significant difference in mean VAS of Group A and B. Only one patient in Group B developed headache.

Conclusion: Thus, both levocetirizine and bepotastine are equally effective for the treatment of CSU. Bepotastine has less sedative potential than levocetirizine.

Key words: Levocetirizine; Bepotastine; Chronic Spontaneous Urticaria; Urticaria Activity Score; Urticaria Control Test


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ashish Kumar Rai
Articles by Shital Poojary
Articles by Lily Dubey
Articles by Pawan Gupta
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Rai AK, Poojary S, Dubey L, Gupta P. A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022


Web Style

Rai AK, Poojary S, Dubey L, Gupta P. A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. https://www.njppp.com/?mno=52351 [Access: September 01, 2022]. doi:10.5455/njppp.2022.12.062871202217062022


AMA (American Medical Association) Style

Rai AK, Poojary S, Dubey L, Gupta P. A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022



Vancouver/ICMJE Style

Rai AK, Poojary S, Dubey L, Gupta P. A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. Natl J Physiol Pharm Pharmacol. (2022), [cited September 01, 2022]; 12(8): 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022



Harvard Style

Rai, A. K., Poojary, . S., Dubey, . L. & Gupta, . P. (2022) A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. Natl J Physiol Pharm Pharmacol, 12 (8), 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022



Turabian Style

Rai, Ashish Kumar, Shital Poojary, Lily Dubey, and Pawan Gupta. 2022. A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022



Chicago Style

Rai, Ashish Kumar, Shital Poojary, Lily Dubey, and Pawan Gupta. "A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022



MLA (The Modern Language Association) Style

Rai, Ashish Kumar, Shital Poojary, Lily Dubey, and Pawan Gupta. "A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria." National Journal of Physiology, Pharmacy and Pharmacology 12.8 (2022), 1216-1221. Print. doi:10.5455/njppp.2022.12.062871202217062022



APA (American Psychological Association) Style

Rai, A. K., Poojary, . S., Dubey, . L. & Gupta, . P. (2022) A double-arm, randomized, and controlled trial to compare the efficacy and safety of bepotastine with levocetirizine in patients of chronic spontaneous urticaria. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1216-1221. doi:10.5455/njppp.2022.12.062871202217062022